BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17373720)

  • 1. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
    Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
    Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
    Calastretti A; Gatti G; Quaresmini C; Bevilacqua A
    Prostate; 2014 Oct; 74(14):1411-22. PubMed ID: 25111376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
    Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
    Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
    Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
    Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer.
    Rochester MA; Riedemann J; Hellawell GO; Brewster SF; Macaulay VM
    Cancer Gene Ther; 2005 Jan; 12(1):90-100. PubMed ID: 15499378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
    Ohigashi T; Mizuno R; Nakashima J; Marumo K; Murai M
    Prostate; 2005 Jan; 62(1):61-8. PubMed ID: 15389810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT and cytosolic phospholipase A2α form a positive loop in prostate cancer cells.
    Hua S; Vignarajan S; Yao M; Xie C; Sved P; Dong Q
    Curr Cancer Drug Targets; 2015; 15(9):781-91. PubMed ID: 26143945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
    Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival.
    Wegiel B; Bjartell A; Culig Z; Persson JL
    Int J Cancer; 2008 Apr; 122(7):1521-9. PubMed ID: 18027847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
    Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
    Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.
    Sun Y; St Clair DK; Fang F; Warren GW; Rangnekar VM; Crooks PA; St Clair WH
    Mol Cancer Ther; 2007 Sep; 6(9):2477-86. PubMed ID: 17876045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms.
    Gill C; Walsh SE; Morrissey C; Fitzpatrick JM; Watson RW
    Prostate; 2007 Nov; 67(15):1641-53. PubMed ID: 17823925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short interfering RNA-induced gene silencing is transmitted between cells from the mammalian central nervous system.
    Zhao TY; Zou SP; Alimova YV; Wang G; Hauser KF; Ghandour MS; Knapp PE
    J Neurochem; 2006 Sep; 98(5):1541-50. PubMed ID: 16923165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.
    Chetram MA; Odero-Marah V; Hinton CV
    Mol Cancer Res; 2011 Jan; 9(1):90-102. PubMed ID: 21076047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells.
    Akca H; Demiray A; Tokgun O; Yokota J
    Lung Cancer; 2011 Sep; 73(3):302-9. PubMed ID: 21333374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms.
    Hudson TS; Hartle DK; Hursting SD; Nunez NP; Wang TT; Young HA; Arany P; Green JE
    Cancer Res; 2007 Sep; 67(17):8396-405. PubMed ID: 17804756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
    St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
    Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.